Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | +8.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.18 | N/A | +8.16% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They remain focused on long-term growth.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Neurocrine Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising by 1.16%. The company did not provide revenue figures or future guidance, leaving some uncertainty. Investors may be encouraged by the EPS beat, suggesting better-than-anticipated cost management or operational efficiency.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NETFLIX INC